Nintedanib* in combination with docetaxel is a treatment for lung cancer patients with advanced adenocarcinoma, after first-line chemotherapy, that targets the three main receptors involved in angiogenesis and tumour growth.¹
*Nintedanib is approved in the EU under the brand name Vargatef^® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is under regulatory review by health authorities in other countries outside the EU. Nintedanib is not approved in other oncology indications.